340 related articles for article (PubMed ID: 30610926)
1. EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer.
Lu S; Yu Y; Li Z; Yu R; Wu X; Bao H; Ding Y; Shao YW; Jian H
J Thorac Oncol; 2019 Apr; 14(4):732-736. PubMed ID: 30610926
[TBL] [Abstract][Full Text] [Related]
2. Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With
Lin X; Peng M; Chen Q; Yuan M; Chen R; Deng H; Deng J; Liu O; Weng Y; Chen M; Zhou C
Front Oncol; 2021; 11():774156. PubMed ID: 34869019
[TBL] [Abstract][Full Text] [Related]
3. Germline EGFR T790M mutation found in multiple members of a familial cohort.
Yu HA; Arcila ME; Harlan Fleischut M; Stadler Z; Ladanyi M; Berger MF; Robson M; Riely GJ
J Thorac Oncol; 2014 Apr; 9(4):554-8. PubMed ID: 24736080
[TBL] [Abstract][Full Text] [Related]
4. Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs).
Zhong J; Li L; Wang Z; Bai H; Gai F; Duan J; Zhao J; Zhuo M; Wang Y; Wang S; Zang W; Wu M; An T; Rao G; Zhu G; Wang J
J Thorac Oncol; 2017 Dec; 12(12):1766-1778. PubMed ID: 28818608
[TBL] [Abstract][Full Text] [Related]
5. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
6. Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations.
Gazdar A; Robinson L; Oliver D; Xing C; Travis WD; Soh J; Toyooka S; Watumull L; Xie Y; Kernstine K; Schiller JH
J Thorac Oncol; 2014 Apr; 9(4):456-63. PubMed ID: 24736066
[TBL] [Abstract][Full Text] [Related]
7. Screening for germline EGFR T790M mutations through lung cancer genotyping.
Oxnard GR; Miller VA; Robson ME; Azzoli CG; Pao W; Ladanyi M; Arcila ME
J Thorac Oncol; 2012 Jun; 7(6):1049-52. PubMed ID: 22588155
[TBL] [Abstract][Full Text] [Related]
8. Discrimination of Germline
Hu Y; Alden RS; Odegaard JI; Fairclough SR; Chen R; Heng J; Feeney N; Nagy RJ; Shah J; Ulrich B; Gutierrez M; Lanman RB; Garber JE; Paweletz CP; Oxnard GR
Clin Cancer Res; 2017 Dec; 23(23):7351-7359. PubMed ID: 28947568
[No Abstract] [Full Text] [Related]
9. Therapeutic Potential of Afatinib for Cancers with
Yamamoto H; Toyooka S; Ninomiya T; Matsumoto S; Kanai M; Tomida S; Kiura K; Muto M; Suzawa K; Desmeules P; Kris MG; Li BT; Ladanyi M
Oncologist; 2018 Feb; 23(2):150-154. PubMed ID: 29146616
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib.
Jia Y; Ali SM; Saad S; Chan CA; Miller VA; Halmos B
Cancer Biol Ther; 2014 Aug; 15(8):970-4. PubMed ID: 24835218
[TBL] [Abstract][Full Text] [Related]
11. EGFR and erbB2 mutation status in Japanese lung cancer patients.
Sasaki H; Shimizu S; Endo K; Takada M; Kawahara M; Tanaka H; Matsumura A; Iuchi K; Haneda H; Suzuki E; Kobayashi Y; Yano M; Fujii Y
Int J Cancer; 2006 Jan; 118(1):180-4. PubMed ID: 16003726
[TBL] [Abstract][Full Text] [Related]
12. Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Chen M; Xu Y; Zhao J; Zhong W; Zhang L; Bi Y; Wang M
EBioMedicine; 2019 Apr; 42():304-310. PubMed ID: 30878600
[TBL] [Abstract][Full Text] [Related]
13. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
[TBL] [Abstract][Full Text] [Related]
15. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
16. Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients.
Yang J; Li H; Li B; Li W; Guo Q; Hu L; Song Z; Zhou B
Front Oncol; 2021; 11():647598. PubMed ID: 33898318
[TBL] [Abstract][Full Text] [Related]
17. Potential genetic modifiers for somatic EGFR mutation in lung cancer: a meta-analysis and literature review.
Cheng YI; Gan YC; Liu D; Davies MPA; Li WM; Field JK
BMC Cancer; 2019 Nov; 19(1):1068. PubMed ID: 31703574
[TBL] [Abstract][Full Text] [Related]
18. EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity.
Vikis H; Sato M; James M; Wang D; Wang Y; Wang M; Jia D; Liu Y; Bailey-Wilson JE; Amos CI; Pinney SM; Petersen GM; de Andrade M; Yang P; Wiest JS; Fain PR; Schwartz AG; Gazdar A; Gaba C; Rothschild H; Mandal D; Kupert E; Seminara D; Viswanathan A; Govindan R; Minna J; Anderson MW; You M
Cancer Res; 2007 May; 67(10):4665-70. PubMed ID: 17510392
[TBL] [Abstract][Full Text] [Related]
19. Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients.
Hashida S; Soh J; Toyooka S; Tanaka T; Furukawa M; Shien K; Yamamoto H; Asano H; Tsukuda K; Hagiwara K; Miyoshi S
Oncol Rep; 2014 Jul; 32(1):145-52. PubMed ID: 24842519
[TBL] [Abstract][Full Text] [Related]
20. High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome.
Mezquita L; Jové M; Nadal E; Kfoury M; Morán T; Ricordel C; Dhooge M; Tlemsani C; Léna H; Teulé A; Álvarez JV; Raimbourg J; Hiret S; Lacroix L; Menéndez M; Saldaña J; Brunet J; Lianes P; Coupier I; Auclin E; Recondo G; Friboulet L; Adam J; Green E; Planchard D; Frébourg T; Capellà G; Rouleau E; Lázaro C; Caron O; Besse B
J Thorac Oncol; 2020 Jul; 15(7):1232-1239. PubMed ID: 32179180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
